WallStSmart
PRAX

Praxis Precision Medicines Inc

NASDAQ: PRAX · HEALTHCARE · BIOTECHNOLOGY

$331.81
-4.06% today

Updated 2026-06-05

Market cap
$7.43B
P/E ratio
P/S ratio
953.14x
EPS (TTM)
$-13.38
Dividend yield
52W range
$37 – $367
Volume
0.4M

Praxis Precision Medicines Inc (PRAX) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20182019202020212022202320242025
Operating cash flow$-20.72M$-32.79M$-52.62M$-124.55M$-185.04M$-111.14M$-131.76M$-249.07M
Capital expenditures$63000.00$103000.00$4000.00$1.05M$444000.00$50000.00$0.00$56000.00
Depreciation
Stock-based comp$579000.00$668000.00$5.21M$22.69M$28.59M$24.86M$41.36M$33.94M
Free cash flow$-20.78M$-32.89M$-52.63M$-125.60M$-185.49M$-111.19M$-131.76M$-249.12M
Investing cash flow
Financing cash flow
Dividends paid$696000.00$811000.00
Share repurchases
Debt repayment
Net change in cash$251.80M$-157.49M$-77.69M

Frequently asked questions

What is Praxis Precision Medicines Inc's revenue?

Praxis Precision Medicines Inc's trailing twelve-month revenue is $7.46M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How much free cash flow does PRAX generate?

PRAX produced $-249.12M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is PRAX's balance sheet healthy?

PRAX holds $357.33M in cash and equivalents against — in long-term debt, on $878.14M of shareholder equity. That debt is best read against the cash flow the business throws off each year.